Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments
China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...
BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...
XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of...
Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China
Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the...
Belgium Bans Ozempic for Weight Loss as Global Shortage Persists
Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...
Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development
Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi...
CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China
Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...
AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions
UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...
BMS and 2seventy Bio’s Abecma Faces FDA Review Extension
The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...
Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...
Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...
Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer
Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...
Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases
Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...
Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...
GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups
GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...
BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...